Gdynia

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease4 trials
• Familial hypercholesterolaemia3 trials
• Stroke3 trials
• High blood pressure1 trial
• Peripheral artery disease1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 35 trials
• Phase 21 trial
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Completed3 trials
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals7 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

Closed trials

• Completed

  An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

  NCT05562934· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Phase 4· Novartis Pharmaceuticals· Source

• Terminated

  Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

  NCT04251533· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source